Understanding how Ikaros variants affect multiple myeloma and treatment response
Official title: Investigating the role Ikaros variants in multiple myeloma pathophysiology and drug sensitivity
Funded at Texas A&m University Health Science Ctr · NIH-11086117 · Data updated 2026-11-12
This study is looking at how certain changes in the Ikaros gene might affect how multiple myeloma develops and how well patients respond to treatments, with the hope of finding better ways to tailor therapies for individuals battling this blood cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | May 8, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $336,421 |
| NIH project number | 5R01CA282251-02 |
| Project ID | NIH-11086117 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with multiple myeloma, particularly those experiencing treatment resistance.
✕Less likely to help
Patients with other types of blood cancers or those without multiple myeloma may not benefit from this research.
What this research studies
This research investigates the role of Ikaros gene variants in the development and treatment response of multiple myeloma, a type of blood cancer. By analyzing how these variants influence the behavior of malignant plasma cells in the bone marrow, the study aims to uncover new prognostic markers that could predict treatment resistance or sensitivity. Patients will be evaluated for specific genetic changes that may affect their disease progression and response to therapies like lenalidomide. The goal is to enhance personalized treatment strategies for individuals with multiple myeloma.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and better outcomes for patients with multiple myeloma.
How similar studies have gone: Previous research has shown promising results in understanding the genetic factors influencing multiple myeloma, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Texas A&m University Health Science Ctr
College Station, United States Active
Researchers
- Principal investigator: Singh, Irtisha — Texas A&m University Health Science Ctr
- Study coordinator: Singh, Irtisha
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.